Dr. Fei Ma 马飞
Chief Physician, Associate Professor
Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences (National Cancer Center), Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Chemotherapy and targeted therapy for breast, lung, gastric, esophageal, colorectal cancers, lymphoma, soft tissue tumors, and germ cell tumors.
Dr. Ma earned a medical doctorate in 2002 from Peking Union Medical College. The doctor focuses on medical oncology and personalized treatment, with clinical experience in chemotherapy and targeted therapy for various common tumors. Dr. Ma also researches tumor risk assessment and prevention, leads national research projects, participated in over 20 clinical trials for new anti-tumor drugs, co-edited six oncology monographs, and published more than 20 academic articles.
Name order: in Chinese the family name comes first (Ma Fei). Papers usually list the name as Fei Ma or Ma F.
Selected publications
325 papers on PubMed matched by name and affiliation; 82 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cancer Biol Ther, 2026 (senior author): Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high-altitude versus low-altitude regions: a multi-center retrospective study. PubMed 42337391
- Cancer Innov, 2026 (senior author): Measure of Innovation: From Clinical Questions to Actionable Evidence. PubMed 42876940
- Cancer Innov, 2026 (senior author): Clinical Advances in Breast Cancer: A Comprehensive Overview of Full-Course Disease Management. PubMed 42621907
- Cancer Innov, 2026 (senior author): Safeguarding the Right to a Whole Life. PubMed 42614803
- Cancer Innov, 2026 (senior author): Low-Dose Antiangiogenic Therapy With Different Chemotherapy Backbones Among Patients With Heavily Pretreated Metastatic Breast Cancer. PubMed 42529520
- Nat Cancer, 2026 (senior author): Dalpiciclib plus endocrine therapy in women with HR(+)/HER2(-) advanced breast cancer and visceral crisis: a multicenter, nonrandomized, phase 2 DARVIN trial. PubMed 42481711
- Chin J Cancer Res, 2026 (senior author): Spatial transcriptome revealed associated biomarkers for endocrine therapy response in HR-positive/HER2-negative early breast cancer. PubMed 42421911
- Breast Cancer (Dove Med Press), 2026 (senior author): Efficacy of CDK4/6 Inhibitor Plus Aromatase Inhibitor versus Fulvestrant in Chinese Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer. PubMed 42371538
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion